Literature DB >> 16971842

Peripheral refraction in orthokeratology patients.

W Neil Charman1, John Mountford, David A Atchison, Emma L Markwell.   

Abstract

PURPOSE: The purpose of this study is to measure refraction across the horizontal central visual field in orthokeratology patients before and during treatment.
METHODS: Refractions were measured out to 34 degrees eccentricity in both temporal and nasal visual fields using a free-space autorefractor (Shin-Nippon SRW5000) for the right eyes of four consecutively presenting myopic adult patients. Measurements were made before orthokeratology treatment and during the course of treatment (usually 1 week and 2 weeks into treatment). Refractions were converted into mean sphere (M), 90 degrees to 180 degrees astigmatism (J180), and 45 degrees to 135 degrees astigmatism (J45) components.
RESULTS: Before treatment, subjects had either a relatively constant mean sphere refraction across the field or a relative hypermetropia in the periphery as compared with the central refraction. As a result of treatment, myopia decreased but at reduced rate out into the periphery. Most patients had little change in mean sphere at 30 degrees to 34 degrees . In all patients, the refraction pattern altered little after the first week.
CONCLUSION: Orthokeratology can correct myopia over the central +/- 10 degrees of the visual field but produces only minor changes at field angles larger than 30 degrees . If converting relative peripheral hypermetropia to relative peripheral myopia is a good way of limiting the axial elongation that leads to myopia, orthokeratology is an excellent option for achieving this.

Entities:  

Mesh:

Year:  2006        PMID: 16971842     DOI: 10.1097/01.opx.0000232840.66716.af

Source DB:  PubMed          Journal:  Optom Vis Sci        ISSN: 1040-5488            Impact factor:   1.973


  21 in total

1.  Central and peripheral autorefraction repeatability in normal eyes.

Authors:  Kelly E Moore; David A Berntsen
Journal:  Optom Vis Sci       Date:  2014-09       Impact factor: 1.973

Review 2.  Optical treatment strategies to slow myopia progression: effects of the visual extent of the optical treatment zone.

Authors:  Earl L Smith
Journal:  Exp Eye Res       Date:  2013-01-03       Impact factor: 3.467

3.  Prentice Award Lecture 2010: A case for peripheral optical treatment strategies for myopia.

Authors:  Earl L Smith
Journal:  Optom Vis Sci       Date:  2011-09       Impact factor: 1.973

4.  Accommodation response and spherical aberration during orthokeratology.

Authors:  L Batres; S Peruzzo; M Serramito; G Carracedo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-11-12       Impact factor: 3.117

5.  Weighted Zernike defocus coefficient of treatment zone is a meaningful indicator for myopia control efficacy of Ortho-K lenses.

Authors:  Yuzhuo Fan; Yan Li; Kai Wang; Jia Qu; Mingwei Zhao
Journal:  Eye Vis (Lond)       Date:  2022-07-01

6.  Peripheral optics with bifocal soft and corneal reshaping contact lenses.

Authors:  Anita Ticak; Jeffrey J Walline
Journal:  Optom Vis Sci       Date:  2013-01       Impact factor: 1.973

7.  Centration and Decentration of Contact Lenses during Peripheral Gaze.

Authors:  Nevin W El-Nimri; Jeffrey J Walline
Journal:  Optom Vis Sci       Date:  2017-11       Impact factor: 1.973

8.  Interventions to slow progression of myopia in children.

Authors:  Jeffrey J Walline; Kristina B Lindsley; S Swaroop Vedula; Susan A Cotter; Donald O Mutti; Sueko M Ng; J Daniel Twelker
Journal:  Cochrane Database Syst Rev       Date:  2020-01-13

9.  Overnight orthokeratology is comparable with atropine in controlling myopia.

Authors:  Hui-Ju Lin; Lei Wan; Fuu-Jen Tsai; Yi-Yu Tsai; Liuh-An Chen; Alicia Lishin Tsai; Yu-Chuen Huang
Journal:  BMC Ophthalmol       Date:  2014-03-31       Impact factor: 2.209

10.  The Spatial Distribution of Relative Corneal Refractive Power Shift and Axial Growth in Myopic Children: Orthokeratology Versus Multifocal Contact Lens.

Authors:  Fan Jiang; Xiaopeng Huang; Houxue Xia; Bingqi Wang; Fan Lu; Bin Zhang; Jun Jiang
Journal:  Front Neurosci       Date:  2021-06-09       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.